Zhibo Xie

Zhibo Xie

Auto-generated profile, based on publicly available information

Zhibo Xie

National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2022 in Journal of Medical Virology
Verified
Journal Article
Closed access
ACAili Cui
Aili Cui
ZXZhibo Xie
Zhibo Xie
JXJing Xu
Jing Xu
KHKongxin Hu
Kongxin Hu
RZRunan Zhu
Runan Zhu
WXWenbo Xu
Wenbo Xu

3 June 2022 in Nutrition
Verified
Journal Article
Closed access
ZXZhibo Xie
Zhibo Xie
ZHZhangyuting He
Zhangyuting He
YYYuqian Ye
Yuqian Ye
YMYilei Mao
Yilei Mao

22 June 2022 in Journal of Medical Virology
Verified
Journal Article
Closed access
ZLZiran Liu
Ziran Liu
ZXZhibo Xie
Zhibo Xie
RSRui Sun
Rui Sun
FZFeng Zhang
Feng Zhang
WXWenbo Xu
Wenbo Xu
YZYan Zhang
Yan Zhang

9 April 2024 in Journal of Medical Virology
Verified
Journal Article
Closed access
ACAili Cui
Aili Cui
BXBaicheng Xia
Baicheng Xia
HJHaoran Jiang
Haoran Jiang
QLQi LI
Qi LI
LSLiwei Sun
Liwei Sun
YZYan Zhang
Yan Zhang

31 August 2022 in Microbiology Spectrum
Verified
Journal Article
Open access
BWBing Wang
Bing Wang
JSJingjing Song
Jingjing Song
JSJinhua Song
Jinhua Song
NMNaiying Mao
Naiying Mao
JLJiayuan Liang
Jiayuan Liang
YZYan Zhang
Yan Zhang
Human respiratory syncytial virus (HRSV) is one of the leading causes of acute lower respiratory infections (ALRI) worldwide. In this study, we first reported an outbreak of severe neonatal pneumonia caused by HRSVB BA9 at a postpartum care center in mainland China.

9 November 2023 in Climacteric
Verified
Journal Article
Closed access
RTR. Tang
R. Tang
ZXZ. Xie
Z. Xie
XRXiangyan Ruan
Xiangyan Ruan
ZZZhe Zhang
Zhe Zhang
MRMinghua Ren
Minghua Ren
QYQi Yu
Qi Yu
This study aimed to compare the efficacy and safety of oral and transdermal estradiol in alleviating menopausal symptoms. A total of 257 recently menopausal women were randomized into two groups. The t-E2 group received transdermal estradiol (2.5 g per day) (n = 128) and the o-E2V group received oral estradiol valerate (2 mg per day) (n = 129) for 24 weeks; both groups received micronized progesterone (200 mg per day). The primary outcome measure is the change in the modified Kupperman Menopausal Index (KMI) after 24 weeks of treatment. Menopausal symptoms were recorded at screening and at 4, 12 and 24 weeks using both the KMI and the Menopause Rating Scale (MRS). Significant amelioration was observed by KMI and MRS scores for both groups after treatment (p < 0.001). The mean KMI scores showed no difference between the two groups. The mean MRS scores were similar between the two groups at baseline and after 4 weeks of treatment. The results showed statistical differences after 12 weeks and 24 weeks of treatment (p = 0.005 and p = 0.011). Both the after-treatment scores minus the baseline scores of KMI and MRS and the incidence of adverse effects showed no difference between the two groups. This study shows that both transdermal and oral estradiol are effective in relieving menopausal symptoms, with little difference in treatment efficacy and safety. ChiCTR2300073146.